31.10.2022
Acino Latin America recognised as a Great Place to Work
We are honoured that Acino Latin America has been recognised, for the second year in a row, as a Great...
Acino
News
28.10.2022
Acino Appoints Sunil Bhilotra as Managing Director and Interim CEO
Zurich, Switzerland – 28 October 2022 – Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced the appointment of...
23.09.2022
Acino Recognizes World Heart Day 2022
Acino, will today commence an awareness programme in recognition of the upcoming World Heart Day on 29 September, 2022 and...
19.07.2022
Acino donates for humanitarian aid in Ukraine
The war in Ukraine means that many Ukrainian people have been displaced and have no longer access to such essentials,...
30.06.2022
Meet Michael Zehringer, Team Lead Stability
Dedication and expertise are key qualities necessary to provide flexible solutions to our customers, and we are lucky to have...
14.06.2022
Acino signs exclusive license agreement with Bioprojet for treatment of narcolepsy and obstructive sleeping apnoea (OSA)
This agreement strengthens Acino’s position in the Central Nervous System (CNS) therapeutic area and paves the way for greater patient...
23.05.2022
Acino committed to expansion and localisation
25.04.2022
Estonia solar panel project
Acino has recently installed solar panels at its facility in Estonia. This move aims to reduce the company’s carbon footprint...
19.04.2022
Acino achieves Level 1 B-BBEE status in South Africa for the third year running
For the third year running, Acino has attained Level 1 B-BBEE status in South Africa. The Broad Based Black Economic...